Catalent has announced it will spend $350 million over several years to expand biologics drug substance and drug product manufacturing capabilities at its Bloomington...
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
Catalent has acquired a 174,000 m2 biologics development and manufacturing facility currently being built by Vaccine Manufacturing and Innovation Centre UK (VMIC) on the...
US CDMO Catalent plans to expand its facility in Shanghai, China, doubling capacity for the temperature-controlled storage and distribution of clinical supplies and...
CDMO Catalent has completed a $10 million project to install large-scale isolator units at its sites in Dartford, UK, and Malvern, Pennsylvania, USA. The facilities will...
Catalent has announced a $230 million expansion project that will add three more commercial-scale viral vector manufacturing suites and associated support facilities and...
As part of a drive to complement its consumer health technology platform with a wider range of technologies and ready-to-market product libraries, as well as a variety of...
DisperSol Technologies, a clinical-stage pharmaceutical company developing new treatments for oncology and rare diseases, has linked up with CDMO Catalent on a strategic...
